Bruce E. Seligmann
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$11.4MFederal grants as PI20 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
20 awards · $11.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 3, 2024 | NIH | SBIR Phase II Whole blood filter paper assay for Alzheimers Disease | $115K | Biospyder Technologies, Inc. |
| Aug 30, 2024 | NIH | SBIR Phase II Whole blood filter paper assay for Alzheimers Disease | $1.1M | Biospyder Technologies, Inc. |
| Jun 5, 2024 | NIH | SBIR Phase II TempO-LINC high throughput high sensitivity single cell gene expression profiling assay Ph II | $1.3M | Biospyder Technologies, Inc. |
| Apr 22, 2024 | NIH | SBIR Phase II Whole blood filter paper assay for Alzheimers Disease | $23K | Biospyder Technologies, Inc. |
| Sep 20, 2023 | NIH | SBIR Phase II Whole blood filter paper assay for Alzheimers Disease | $1.4M | Biospyder Technologies, Inc. |
| Aug 25, 2021 | NIH | SBIR Phase II TempO-Seq Profiling of RNA Epitranscriptomic Modifications | $477K | Biospyder Technologies, Inc. |
| Dec 25, 2020 | NIH | SBIR Phase I TempO-Seq assay and cell panel for assessing impact of genetic diversity on compound bioactivity and toxicity risk | $252K | Biospyder Technologies, Inc. |
| Aug 11, 2020 | NIH | SBIR Phase I Functional Read-Out Enabling High Compound Throughput Toxicokinetic Assays | $225K | Biospyder Technologies, Inc. |
| Jul 24, 2020 | NIH | SBIR Phase I TempO-Vseq Screen for Genomic Risk of CAD Using Blood from a Finger Prick | $409K | Biospyder Technologies, Inc. |
| Sep 19, 2019 | NIH | SBIR Phase II TempO-Seq Profiling of RNA Epitranscriptomic Modifications | $70K | Biospyder Technologies, Inc. |
| Jul 31, 2019 | NIH | SBIR Phase I Whole Blood Filter Paper Assay for Alzheimers Disease | $437K | Biospyder Technologies, Inc. |
| Sep 24, 2018 | NIH | SBIR Phase II TempO-Seq Gene Expression Profiling of Intracellular Stained FACS Sorted Cells | $394K | Biospyder Technologies, Inc. |
| Sep 17, 2018 | NIH | SBIR Phase II TempO-Seq Profiling of RNA Epitranscriptomic Modifications | $224K | Biospyder Technologies, Inc. |
| Jun 22, 2018 | NIH | SBIR Phase II TempO-Seq for Preserved Tissues in Toxicity Testing Phase II | $505K | Biospyder Technologies, Inc. |
| Sep 15, 2017 | NIH | SBIR Phase II TempO-Seq Gene Expression Profiling of Intracellular Stained FACS Sorted Cells | $1.9M | Biospyder Technologies, Inc. |
| Jul 14, 2017 | NIH | SBIR Phase II Multiplexed mRNA and miRNA Profiling of Single Cells Phase II | $499K | Biospyder Technologies, Inc. |
| Jun 29, 2017 | NIH | SBIR Phase II TempO-Seq for Preserved Tissues in Toxicity Testing Phase II | $980K | Biospyder Technologies, Inc. |
| Sep 22, 2016 | NIH | SBIR Phase II Multiplexed mRNA and miRNA Profiling of Single Cells Phase II | $499K | Biospyder Technologies, Inc. |
| Jul 27, 2015 | NIH | SBIR Phase I RASL-Seq CTC Assay | $350K | Biospyder Technologies, Inc. |
| Mar 26, 2015 | NIH | SBIR Phase I In Situ RNA-FISH with Localized Profiling by Sequencing from FFPE | $213K | Biospyder Technologies, Inc. |
Peer ranks
Federal funding#48
Awards as PI#18
Patents#273
Companies
- Biospyder Technologies, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.